Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-course radiotherapy plus ipilimumab, bevacizumab, and capecitabine as total neoadjuvant therapy for MSS/pMMR locally advanced rectal cancer
ChiCTR2600120484Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, bevacizumab and capecitabine in rectal adenocarcinoma, sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: Pathologic complete response (pCR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ipilimumabbevacizumabcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600120484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120484.